Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase II clinical trial (investigates the efficacy of combining gemcitabine, a chemotherapy agent, with ivonescimab, a bispecific PD-1/VEGF antibody, in patients with advanced non-small cell lung cancer (NSCLC) who have experienced disease progression following chemoimmunotherapy (CIT). Lung cancer remains the leading cause of cancer-related death globally, and treatment options after CIT failure are limited. Gemcitabine has demonstrated immunostimulatory properties, including enhanced T-cell infiltration and reduced immunosuppressive cell populations, which may synergize with immune checkpoint inhibitors. Ivonescimab targets both PD-1 and VEGF pathways, potentially enhancing antitumor immune responses and inhibiting tumor angiogenesis. The trial aims to evaluate the objective response rate (ORR) according to RECIST v1.1 criteria. The combination therapy is expected to offer a novel and effective treatment strategy for patients with relapsed NSCLC, addressing a significant unmet medical need.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaawansowany rak płuc (stadium IIIB-IV) z nawrotem lub progresją mimo wcześniejszej immunoterapii
- •Obecne przerzuty do mózgu są dopuszczalne, jeśli zostały leczone i są stabilne od co najmniej 4 tygodni
- •Pacjenci z HIV mogą uczestniczyć, jeśli liczba CD4 jest wystarczająca i wirus jest kontrolowany
- •Wiek od 18 lat
- •Dobra funkcja szpiku kostnego (wystarczająca liczba białych krwinek, płytek krwi i hemoglobiny)
- •Dobra funkcja wątroby
- •Możliwość zebrania próbki guza do badań
- •Ogólny stan zdrowia pozwalający na aktywne leczenie
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Kantonsspital Baden
Baden, Switzerland
Universitätsspital Basel
Basel, Switzerland
IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, Switzerland
Kantonsspital Graubuenden
Chur, Switzerland
Hôpital Fribourgeois - Hôpital Cantonal
Fribourg, Switzerland
Hôpitaux Universitaires de Genève
Geneva, Switzerland
Kantonsspital Winterthur
Winterthur, Switzerland
Trial contact
Jana Musilova, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.